Philip Q Bao, MD, Kevin T Watkins, MD. Stony Brook University Medical Center
Controversy remains as to the optimal indications for resection of cystic pancreatic neoplasms. Minimally invasive pancreatic surgery is being more widely adopted. The risk/benefit decision for resection of cystic pancreatic neoplasms needs to consider the morbidity and mortality of the surgical procedures. We chose to evaluate our experience with minimally invasive pancreatic resection for cystic neoplasms. METHODS: A retrospective review was conducted on all patients undergoing minimally invasive pancreatic resection for cystic lesions from 1/2005 to 9/2011. RESULTS: 41 minimally invasive pancreatic resections were performed for cystic lesions by preoperative imaging. Pathologies are listed in Table 1. There were 3 total pancreatectomies, 5 pancreatico-duodenectomies(PD), and 33 distal resections. Length of stay (LOS) was 6+/-1, 12.5+/-11.7, and 3.1+/-1.7 days for total, PD, and distal resections respectively. Blood loss and operative times are displayed in Fig 1. A single mortality (2.4%) occurred in the PD group from stroke. Morbidity for total, PD, and distal was 0%, 60%, and 15% respectively. No pancreatic fistulae occurred in the distal resection group. Conclusions: Minimally invasive pancreatic resection for cystic neoplasms can be performed with similar morbidity and mortality to open procedures. Distal resections may offer lower morbidity than open procedures. Further evaluation is necessary for the indications for distal resection for cystic neoplasms.
| IPMN | 16 |
|---|---|
| Serous Cystadenoma | 12 |
| Mucinous Cystic Neoplasm | 5 |
| Solid Pseudopapillary | 3 |
| Lymphoepithelial Cyst | 2 |
| Pancreatitis | 1 |
| Pancreatic Cancer | 1 |
| Neuroendocrine |
1 |
Session Number: Poster – Poster Presentations
Program Number: P400
View Poster